000			03313nam a22004937a 4500
008			170918s20172017 xxu||||| |||| 00| 0 eng d
022			_a0265-6736
040			_aOvid MEDLINE(R)
099			_a28877609
245			_aCytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial and recurrent ovarian carcinoma: a single center experience.
251			_aInternational Journal of Hyperthermia. 34(5):564-569, 2018 08.
252			_aInt J Hyperthermia. 34(5):564-569, 2018 08.
253			_aInternational journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
260			_c2018
260			_fFY2019
266			_d2017-09-18
269			_fFY2018
520			_aBACKGROUND: With standard treatment of epithelial ovarian cancer (EOC), prognosis is very poor. The aim of this study is to show early and late results in patients who underwent cytoreductive surgery and intraperitoneal chemotherapy.
520			_aCONCLUSIONS: In advanced or recurrent EOC, a curative therapeutic approach was pursued that combined optimal cytoreductive surgery and intraperitoneal chemotherapy. PCI and timing of the intervention (primary or recurrent) were the strongest independent prognostic factors.
520			_aPATIENTS AND METHODS: This was a retrospective single centre study. All patients with advanced and recurrent ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) or modified early postoperative intraperitoneal chemotherapy (EPIC) were included in the study.
520			_aRESULTS: In the period 1995-2014, 116 patients were treated, 55 with primary EOC and 61 with recurrent EOC. The mean age was 59 years (26-74). Statistically, median survival time was significantly longer in the group with primary advanced cancer of the ovary (41.3 months) compared to relapsed ovarian cancer (27.3 months). Survival for the primary EOC was 65 and 24% at 3 and 5 years, respectively. Survival for recurrent EOC was 33 and 16% at 3 and 5 years, respectively. Mortality was 1/116 (0.8%). Morbidity was 11/116 (9.5%). Peritoneal cancer index (PCI) was <=20 in 59 (51%) patients and statistically, their average survival was significantly longer than in the group of 57 (49%) patients with PCI>20 (p=0.014).
546			_aEnglish
650			_a*Cytoreduction Surgical Procedures/mt [Methods]
650			_a*Hyperthermia, Induced/mt [Methods]
650			_a*Ovarian Neoplasms/dt [Drug Therapy]
650			_a*Ovarian Neoplasms/su [Surgery]
650			_aAdult
650			_aAged
650			_aFemale
650			_aHumans
650			_aMiddle Aged
650			_aNeoplasm Recurrence, Local
650			_aOvarian Neoplasms/mo [Mortality]
650			_aOvarian Neoplasms/pa [Pathology]
650			_aPrognosis
650			_aRetrospective Studies
650			_aSurvival Analysis
651			_aWashington Cancer Institute
657			_aJournal Article
700			_aSugarbaker, Paul H
790			_aCeranic MS, Kecmanovic DM, Latincic SM, Pavlov MJ, Sabljak PV, Sugarbaker PH
856			_uhttps://dx.doi.org/10.1080/02656736.2017.1371341 _zhttps://dx.doi.org/10.1080/02656736.2017.1371341
942			_cART _dArticle
999			_c2674 _d2674